LYON, France–(BUSINESS WIRE)–Regulatory Information:
POXEL SA ( Euronext (EPA:): POXEL – FR0012432516), a scientific stage biopharmaceutical firm growing modern therapies for power critical ailments with metabolic pathophysiology, together with metabolic dysfunction-associated steatohepatitis (MASH) and uncommon metabolic issues, immediately introduced the provision of its half-year monetary report as of June 30, 2024.
The half-year monetary report contains:
- the condensed consolidated monetary statements for the primary half of 2024, as of June 30, 2024;
- the half-year exercise report;
- the certification of the particular person chargeable for the half-year monetary report;
- the Statutory Auditors’ restricted assessment report on the half-year monetary info, which incorporates an incapability to achieve a conclusion because of the uncertainties surrounding going concern.
This doc is obtainable in French on Poxel’s web site www.poxelpharma.com within the Buyers / Shareholder Data / Regulatory Documentation part.
About Poxel SA (EPA:)
Poxel is a scientific stage biopharmaceutical firm growing modern therapies for power critical ailments with metabolic pathophysiology, together with metabolic dysfunction-associated steatohepatitis (MASH) and uncommon issues. For the remedy of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its major endpoint in a streamlined Part 2 trial (DESTINY-1). In uncommon ailments, improvement of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is concentrated on the remedy of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney illness (ADPKD). TWYMEEG ® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the remedy of sort 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to obtain royalties and sales-based funds. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For extra info, please go to: www.poxelpharma.com
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241222638171/en/
Investor relations / Media
NewCap
Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
investor@poxelpharma.com
+33 1 44 71 94 94
Supply: Poxel SA
